TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28344345

Group type: EXPERIMENTAL
Intervention: Exercise program (EX)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 22
Study: 25884810

Group type: EXPERIMENTAL
Intervention: History of foster care placement
Number of subjects: 442

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 442
Study: 24248687

Group type: EXPERIMENTAL
Intervention: Lapatinib (Arm A)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Combination of Lapatinib and Trastuzumab (Arm C)
Number of subjects: 306
Study: 20603436

Group type: EXPERIMENTAL
Intervention: Cetuximab
Number of subjects: 572
Study: 19357536

Group type: EXPERIMENTAL
Intervention: Annual low dose CT scans for 5 years
Number of subjects: 4104

Group type: COMPARATOR
Intervention: No screening
Number of subjects: 4104
Study: 17846074

Group type: EXPERIMENTAL
Intervention: Falls prevention exercise programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study: 15480130

Group type: EXPERIMENTAL
Intervention: Manipulative Therapy (MT)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Interferential Therapy (IFT)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Combination Therapy (CT)
Number of subjects: 240
Study: 11782693

Group type: EXPERIMENTAL
Intervention: Extraperitoneal approach
Number of subjects: 20

Group type: COMPARATOR
Intervention: Transperitoneal approach
Number of subjects: 20
Study: 9507846

Group type: EXPERIMENTAL
Intervention: Repeat sextant prostate biopsy
Number of subjects: 118

Group type: COMPARATOR
Intervention: Initial clinical stage
Number of subjects: 118
Study: 8062353

Group type: EXPERIMENTAL
Intervention: 6 mg sumatriptan
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 29068153

Group type: EXPERIMENTAL
Intervention: ciNPT (PREVENA™ Therapy)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control dressing (conventional adhesive plaster)
Number of subjects: 100
Study: 26413789

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 2

Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 2

Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 2
Study: 24535360

Group type: EXPERIMENTAL
Intervention: Propofol TCI + 0.8 μg/kg fentanyl
Number of subjects: 58

Group type: COMPARATOR
Intervention: Propofol TCI + 40 mg lidocaine
Number of subjects: 58
Study: 22762231

Group type: EXPERIMENTAL
Intervention: Intensive quit‐smoking intervention (n = 148)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Usual care (n = 115)
Number of subjects: 263
Study: 20584655

Group type: EXPERIMENTAL
Intervention: CVVH plus CPFA
Number of subjects: 30

Group type: COMPARATOR
Intervention: CVVH alone
Number of subjects: 30
Study: 17889865

Group type: EXPERIMENTAL
Intervention: Vitrification by the Cryotop method
Number of subjects: 60
Study: 17072055

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids for 2 months
Number of subjects: 41
Study: 12858196

Group type: EXPERIMENTAL
Intervention: Blood stem cells (BSC)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Bone marrow (BM)
Number of subjects: 61
Study: 10831691

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (Gd‐BOPTA) 0.05‐mmol/kg dose administered before and after imaging
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (Gd‐BOPTA) 0.1‐mmol/kg dose administered before and after imaging
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (Gd‐BOPTA)
Number of subjects: 214
Study: 8800891

Group type: EXPERIMENTAL
Intervention: No antibiotics perioperatively (Group I)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Co-trimoxazole for 5 days (Group II)
Number of subjects: 116
Study: 1997058

Group type: EXPERIMENTAL
Intervention: Ingestion of unlimited clear fluids up to 3 h before surgery
Number of subjects: 152

Group type: COMPARATOR
Intervention: Nothing by mouth after midnight (control group)
Number of subjects: 152
Study: 6229892

Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lincomycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rifampin
Number of subjects: 0
Study: 29589991

Group type: EXPERIMENTAL
Intervention: Community Health Campaigns (CHCs)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Government Clinics
Number of subjects: 12
Study: 27220574

Group type: EXPERIMENTAL
Intervention: Catheter ablation using domestic 3D cardiac electrophysiological mapping system
Number of subjects: 255

Group type: COMPARATOR
Intervention: Antiarrhythmics drugs cardioversion
Number of subjects: 255
Study: 24764640

Group type: EXPERIMENTAL
Intervention: Standing position
Number of subjects: 30

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 30
Study: 22872251

Group type: EXPERIMENTAL
Intervention: Christmas tree foreheadplasty with supraorbital bandeau
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (age-matched normal controls)
Number of subjects: 32
Study: 20148906

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg/day) and Diet alone
Number of subjects: 49
Study: 18597226

Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (standard propofol titration)
Number of subjects: 56
Study: 15780550

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 12018972

Group type: COMPARATOR
Intervention: Sorbitol (1305 mg)
Number of subjects: 85
Study: 10622070

Group type: EXPERIMENTAL
Intervention: Clarithromycin (500 mg) every 12 hours for 5-10 days
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Spiramycin (3 MIU) every 12 hours for 5-10 days
Number of subjects: 125
Study: 7575745

Group type: EXPERIMENTAL
Intervention: New sotalol hydrochloride tablet (160 mg)
Number of subjects: 16
Study: 1835157

Group type: EXPERIMENTAL
Intervention: Spinal flexion exercises
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spinal extension exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 6128546

Group type: EXPERIMENTAL
Intervention: Oral captopril
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Albumin infusion
Number of subjects: 16
Study: 31055522

Group type: EXPERIMENTAL
Intervention: Experiential learning in communication skills training
Number of subjects: 20
Study: 30026514

Group type: EXPERIMENTAL
Intervention: Jerusalem artichoke and fermented soybean powder mixture (40g daily for 12 weeks)
Number of subjects: 60
Study: 27528117

Group type: EXPERIMENTAL
Intervention: Androgen suppression (secondary treatment)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Number of bony metastatic sites
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Other sites of progression
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Further bony metastatic progression in men with up to 3 bony metastases
Number of subjects: 176
Study: 26875300

Group type: EXPERIMENTAL
Intervention: Low-dose ferric EDTA (2.5 mg of iron)
Number of subjects: 139

Group type: COMPARATOR
Intervention: High-dose ferrous lactate (10 mg of iron)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 139
Study: 22424608

Group type: EXPERIMENTAL
Intervention: Questionnaire included in the invitation package
Number of subjects: 500

Group type: COMPARATOR
Intervention: No questionnaire included in the invitation package
Number of subjects: 500
Study: 19767320

Group type: EXPERIMENTAL
Intervention: Smokefree Class Competition (intervention group)
Number of subjects: 3123

Group type: COMPARATOR
Intervention: Control group (classes that refrained from smoking)
Number of subjects: 3123
Study: 18697192

Group type: EXPERIMENTAL
Intervention: Amino acid solution inducing hyperammonemia
Number of subjects: 16

Group type: COMPARATOR
Intervention: Phosphate-buffered saline (control)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 75 microM ammonia
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: p38(MAPK) agonist
Number of subjects: 16
Study: 15813840

Group type: EXPERIMENTAL
Intervention: ondansetron 8 mg intravenous bolus followed by oral ondansetron 8 mg twice daily for 5 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study: 12560224

Group type: EXPERIMENTAL
Intervention: New designs for phase 2 clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized selection trials evaluating several therapies based on multiple outcomes
Number of subjects: 0
Study: 10728540

Group type: EXPERIMENTAL
Intervention: Toughened glassware
Number of subjects: 1229

Group type: COMPARATOR
Intervention: Annealed glassware (control)
Number of subjects: 1229
Study: 9446305

Group type: EXPERIMENTAL
Intervention: Inhalations of hydrogen sulfide water
Number of subjects: 77

Group type: COMPARATOR
Intervention: Conventional regimen (controls)
Number of subjects: 77
Study: 8478660

Group type: EXPERIMENTAL
Intervention: Doxorubicin-containing therapy (CHOP: cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Doxorubicin-containing therapy (CHOP)
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 415
Study: 3092659

Group type: EXPERIMENTAL
Intervention: enprostil (35 micrograms twice daily)
Number of subjects: 369

Group type: COMPARATOR
Intervention: cimetidine (400 mg twice daily)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: enprostil
Number of subjects: 369

Group type: COMPARATOR
Intervention: cimetidine
Number of subjects: 369
Study: 30379624

Group type: EXPERIMENTAL
Intervention: Documented cardiotoxicity during on-protocol therapy
Number of subjects: 1022

Group type: EXPERIMENTAL
Intervention: Incident cardiotoxicity event in absence of infection
Number of subjects: 1022

Group type: EXPERIMENTAL
Intervention: Incident cardiotoxicity event in presence of infection
Number of subjects: 1022

Group type: EXPERIMENTAL
Intervention: Non-infection associated cardiotoxicity
Number of subjects: 1022

Group type: EXPERIMENTAL
Intervention: Infection-associated cardiotoxicity
Number of subjects: 1022
Study: 30630782

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 140

Group type: COMPARATOR
Intervention: Sodium valproate
Number of subjects: 140
Study: 27479339

Group type: EXPERIMENTAL
Intervention: CAD/CAM splint
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional splint
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 48
Study: 24790826

Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block with bupivacaine
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 23342679

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A plus upper limb therapy programme
Number of subjects: 333

Group type: COMPARATOR
Intervention: Upper limb therapy programme alone
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A plus therapy
Number of subjects: 333
Study: 21196929

Group type: EXPERIMENTAL
Intervention: Sertraline (100 mg/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 16703311

Group type: COMPARATOR
Intervention: iomeprol 300 (iodine concentration: 300 mg/ml)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: iomeprol 400 (iodine concentration: 400 mg/ml)
Number of subjects: 21
Study: 16076919

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly plus calcium carbonate 500 mg daily
Number of subjects: 58

Group type: COMPARATOR
Intervention: Calcium carbonate 500 mg daily
Number of subjects: 58
Study: 11998525

Group type: EXPERIMENTAL
Intervention: Palatopharyngeal surgery (four different surgical techniques)
Number of subjects: 0
Study: 10407719

Group type: EXPERIMENTAL
Intervention: Surviving Cancer Competently Intervention Program (SCCIP) - a one-day family group intervention combining cognitive-behavioral and family therapy approaches
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Surviving Cancer Competently Intervention Program (SCCIP)
Number of subjects: 19
Study: 7761740

Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sleep Deprivation with Continuous Physical Work (SDW)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sleep Deprivation (SD) and Sleep Deprivation with Continuous Physical Work (SDW)
Number of subjects: 19
Study: 1967946

Group type: EXPERIMENTAL
Intervention: suxamethonium
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: vecuronium
Number of subjects: 43
Study: 6767517

Group type: EXPERIMENTAL
Intervention: Oral administration of 50 g of mannitol 2 hours before whole bowel irrigation (WBI)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Whole bowel irrigation (WBI) alone
Number of subjects: 42
Study: 28741061

Group type: EXPERIMENTAL
Intervention: CM formula (10 herbs) for 4 weeks
Number of subjects: 122

Group type: COMPARATOR
Intervention: Antibiotics for 1 week followed by 3 weeks of placebo
Number of subjects: 122
Study: 27918731

Group type: EXPERIMENTAL
Intervention: Passiflora incarnata (260 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Midazolam (15 mg)
Number of subjects: 40
Study: 25140866

Group type: EXPERIMENTAL
Intervention: 2 mg guanfacine (n=50)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (n=34)
Number of subjects: 84
Study: 23370985

Group type: EXPERIMENTAL
Intervention: Intramedullary (IM) repair
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Plate repair
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IM device removal
Number of subjects: 30

Group type: COMPARATOR
Intervention: Plate removal
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intact clavicle
Number of subjects: 30
Study: 23470990

Group type: COMPARATOR
Intervention: Placebo CPAP
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 25
Study: 20334477

Group type: EXPERIMENTAL
Intervention: Fasting for 6 hours after a rice meal (R6)
Number of subjects: 212

Group type: COMPARATOR
Intervention: Fasting for 10 hours after a rice meal (R10)
Number of subjects: 212
Study: 17669545

Group type: EXPERIMENTAL
Intervention: Kids Choice Program
Number of subjects: 0
Study: 16419687

Group type: EXPERIMENTAL
Intervention: Sodium enoxaparin, administered subcutaneously at a dose of 2,000 IU twice daily for 10 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 12049575

Group type: EXPERIMENTAL
Intervention: Topical ocular hypotensive medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline factors (age, cup-disc ratio, intraocular pressure, pattern standard deviation, central corneal thickness)
Number of subjects: 0
Study: 9443710

Group type: EXPERIMENTAL
Intervention: Peptide T (2 mg, intranasally, 3 times a day for 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8544654

Group type: EXPERIMENTAL
Intervention: Dark-blood MRI with semiautomated image processing
Number of subjects: 4

Group type: COMPARATOR
Intervention: Bright-blood MRA
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Dark-blood MRI
Number of subjects: 4
Study: 2677429

Group type: EXPERIMENTAL
Intervention: Zidovudine therapy
Number of subjects: 229
Study: 7152082

Group type: EXPERIMENTAL
Intervention: Disophrol Syrup
Number of subjects: 78

Group type: COMPARATOR
Intervention: Rinomar Syrup
Number of subjects: 78
Study: 31628085

Group type: EXPERIMENTAL
Intervention: Ensartinib 225 mg orally once daily
Number of subjects: 160
Study: 30990762

Group type: EXPERIMENTAL
Intervention: Pilates exercise programme (60-minute sessions for 12 weeks)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 110
Study: 28393439

Group type: EXPERIMENTAL
Intervention: AAV1/SERCA2a
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 26508711

Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 1790
Study: 23652578

Group type: EXPERIMENTAL
Intervention: 0.5 mg of ranibizumab monthly for 12 months
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 0.5 mg of ranibizumab monthly for 3 months and then pro re nata
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: high-dose 2.0 mg of ranibizumab monthly for 12 months
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 2.0 mg of ranibizumab monthly for 3 months and then pro re nata thereafter
Number of subjects: 37

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 37
Study: 22159381

Group type: EXPERIMENTAL
Intervention: Reverse breech extraction
Number of subjects: 118

Group type: COMPARATOR
Intervention: Conventional method (control)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 118
Study: 19389714

Group type: EXPERIMENTAL
Intervention: 6 mg/kg daptomycin administered as a 30 min iv infusion
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 6 mg/kg daptomycin administered as a 2 min iv injection
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 4 mg/kg daptomycin administered as a 2 min iv injection
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 19046587

Group type: EXPERIMENTAL
Intervention: Glycine (60g/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Glycine
Number of subjects: 24
Study: 15036854

Group type: EXPERIMENTAL
Intervention: Cs-137 low-dose-rate brachytherapy (60-75 Gy at 1.4-1.8 Gy/h)
Number of subjects: 517

Group type: COMPARATOR
Intervention: Ra-226 low-dose-rate brachytherapy (75 Gy at 0.5 Gy/h)
Number of subjects: 517
Study: 12205256

Group type: EXPERIMENTAL
Intervention: Thyroxine (T4) treatment
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 9220504

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl combined with midazolam
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Intramuscular meperidine‐promethazine‐chlorpromazine (MPC) compound
Number of subjects: 42
Study: 8380697

Group type: EXPERIMENTAL
Intervention: Vincristine, ifosfamide, mesna and carboplatin (VIMP)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Cyclophosphamide, doxorubicin and etoposide (CDE)
Number of subjects: 68
Study: 2443087

Group type: EXPERIMENTAL
Intervention: 3% NaCl (12 mL/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7.5% NaCl/dextran 70 (250 mL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 0
Study: 12362423

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 2 gm/kg at induction and 1 gm/kg after 3 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: 5% albumin placebo
Number of subjects: 15
Study: 30175333

Group type: EXPERIMENTAL
Intervention: Active varnish (Fluor Protector S; 7,700 ppm F)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 12
Study: 27411331

Group type: EXPERIMENTAL
Intervention: mindfulness intervention
Number of subjects: 68

Group type: COMPARATOR
Intervention: relaxation intervention
Number of subjects: 68
Study: 24886348

Group type: EXPERIMENTAL
Intervention: Acupuncture plus auricular acupressure (AA group)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Climen (control group)
Number of subjects: 206
Study: 22672587

Group type: EXPERIMENTAL
Intervention: Change4Life (C4L) campaign materials including print materials and personalized feedback from the 'How are the Kids' questionnaire.
Number of subjects: 3774

Group type: EXPERIMENTAL
Intervention: Change4Life (C4L) campaign materials.
Number of subjects: 3774

Group type: EXPERIMENTAL
Intervention: Change4Life (C4L) campaign materials with personalized feedback.
Number of subjects: 3774

Group type: COMPARATOR
Intervention: Control group (usual care).
Number of subjects: 3774
Study: 20666811

Group type: EXPERIMENTAL
Intervention: Visual Inspection
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Curettage
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Dermoscopy
Number of subjects: 54
Study: 18811573

Group type: EXPERIMENTAL
Intervention: Laparoscopic nephrectomy (LN group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Open nephrectomy (ON group)
Number of subjects: 52
Study: 16043828

Group type: EXPERIMENTAL
Intervention: Carboplatin and paclitaxel with erlotinib
Number of subjects: 274

Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel with placebo
Number of subjects: 274
Study: 12443959

Group type: EXPERIMENTAL
Intervention: Third-generation oral contraceptives (specific dosage and duration not mentioned)
Number of subjects: 186
Study: 10496384

Group type: EXPERIMENTAL
Intervention: AGIS method
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: CIGTS method
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: EMGT method
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Clinical assessment
Number of subjects: 56
Study: 7729632

Group type: EXPERIMENTAL
Intervention: Screening (colonoscopy or barium enema and sigmoidoscopy every 3 years)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Control (no screening)
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: Overall mortality in study group
Number of subjects: 251

Group type: COMPARATOR
Intervention: Overall mortality in control group
Number of subjects: 251
Study: 1781523

Group type: EXPERIMENTAL
Intervention: Clonidine (two doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline (inert treatment)
Number of subjects: 0
Study: 7008894

Group type: EXPERIMENTAL
Intervention: Topical povidone-iodine
Number of subjects: 627

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 627
Study: 30579372

Group type: EXPERIMENTAL
Intervention: Precooling (PC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 12
Study: 28560779

Group type: COMPARATOR
Intervention: S‐(‐)‐amlodipine 2.5 mg/d (low dose)
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: S‐(‐)‐amlodipine 5 mg/d (high dose)
Number of subjects: 523

Group type: COMPARATOR
Intervention: Comparison between high and low dose groups
Number of subjects: 523
Study: 24711660

Group type: EXPERIMENTAL
Intervention: Aerobic training (AT)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Balance and tone training (BAT)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Resistance training (RT)
Number of subjects: 86